Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIRRELL T JOHNSON

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1518042415
CMS profile
204048
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$367.61

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $367.61 7

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $125.93 2
Sun Pharmaceutical Industries Inc. $113.85 1
Davol Inc. $55.46 1
AstraZeneca Pharmaceuticals LP $53.67 2
Medtronic, Inc. $18.70 1

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIRRELL T JOHNSON

NPI 1518042415 · CMS profile ID 204048

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518042415?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIRRELL T JOHNSON, NPI 1518042415, CMS profile ID 204048. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518042415?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). TIRRELL T JOHNSON, NPI 1518042415, CMS profile ID 204048. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518042415?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
TIRRELL T JOHNSON, NPI 1518042415, CMS profile ID 204048, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1518042415?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $367.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Davol Inc. $55.4612/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023929909 CMS
AstraZeneca Pharmaceuticals LP $24.0012/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011519128 CMS
Sun Pharmaceutical Industries Inc. $113.8511/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053988263 CMS
AstraZeneca Pharmaceuticals LP $29.6711/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015387285 CMS
Janssen Biotech, Inc. $101.9408/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988169967 CMS
Janssen Biotech, Inc. $23.9908/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988169953 CMS
Medtronic, Inc. $18.7006/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025848395 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $11.92 1
PY2022 $12.94 1
PY2023 $367.61 7
PY2024 $230.02 3
PY2025 $303.63 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,665,235.05 404
PY2024 Principal investigator $475,494.74 62
PY2023 Principal investigator $95,270.20 17
PY2022 Principal investigator $226,118.71 15
PY2021 Principal investigator $31,342.00 7
PY2020 Principal investigator $82,456.06 7
PY2019 Principal investigator $37,669.74 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

404 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $8,820.83 12/31/2025 Covered Recipient Teaching Hospital
Orlando Health
A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOTE 158 No dispute reported 06/30/2026 1232926287
Principal investigator 1 PFIZER INC. $150.00 12/23/2025 Covered Recipient Teaching Hospital
Orlando Health
A PHASE 2 STUDY OF CONTINUOUS TALAZOPARIB PLUS INTERMITTENT LOWDOSE TEMOZOLOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY EXTENSIVESTAGE SMALL CELL LUNG CANCER TRIOUS L07 WI235082 No dispute reported 06/30/2026 1228721661
Principal investigator 1 Janssen Research & Development, LLC $4,555.00 12/22/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175392358
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $289.28 12/17/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997780
Principal investigator 1 Janssen Research & Development, LLC $810.00 12/12/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1175392263
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,495.00 12/11/2025 Covered Recipient Teaching Hospital
Orlando Health
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220818356
Principal investigator 1 Janssen Research & Development, LLC $3,480.00 12/08/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175392233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 12/08/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134673
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,150.00 12/05/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818340
Principal investigator 1 Janssen Research & Development, LLC $500.00 12/04/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175392381
Principal investigator 1 ModernaTX, Inc. $1,000.00 12/03/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946694
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,250.00 12/02/2025 Covered Recipient Teaching Hospital
Orlando Health
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220818354
Principal investigator 1 Immunocore Limited $1,000.00 12/01/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146051
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,000.00 12/01/2025 Covered Recipient Teaching Hospital
Orlando Health
81990 No dispute reported 06/30/2026 1252498745
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,322.59 12/01/2025 Covered Recipient Teaching Hospital
Orlando Health
81990 No dispute reported 06/30/2026 1252498749
Principal investigator 1 ModernaTX, Inc. $11,200.50 11/28/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971177
Principal investigator 1 ModernaTX, Inc. $1,179.00 11/28/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 11/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 11/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 11/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 11/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 11/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 11/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 11/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 11/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 11/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 11/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 11/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99.56 11/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 11/26/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 11/26/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134635
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,869.20 11/24/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818338
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 11/20/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175392257
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $104.94 11/19/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220997722
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $299.70 11/19/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220997724
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,954.30 11/19/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997760
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $43.95 11/19/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997762
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $314.82 11/19/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997764
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $719.28 11/19/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997766
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,285.00 11/19/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997768
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,297.78 11/19/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997770
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,063.40 11/19/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997772
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1.80 11/19/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997774
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $105.00 11/19/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997776
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $378.00 11/19/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997778
Principal investigator 1 Janssen Research & Development, LLC $5,450.00 11/14/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1175392193
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 11/13/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818336
Principal investigator 1 Iovance Biotherapeutics, Inc. $32.80 11/12/2025 Covered Recipient Teaching Hospital
Orlando Health
81990 No dispute reported 06/30/2026 1252498753
Principal investigator 1 ModernaTX, Inc. $70,658.13 11/12/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 11/10/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 11/10/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 11/10/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 11/10/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 11/10/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134619
Principal investigator 1 Janssen Research & Development, LLC $13,866.40 11/06/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175392088
Principal investigator 1 ModernaTX, Inc. $6,274.90 11/05/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946722
Principal investigator 1 ModernaTX, Inc. $4,585.00 11/05/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971181
Principal investigator 1 ModernaTX, Inc. $3,537.00 11/05/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971205
Principal investigator 1 ModernaTX, Inc. $917.00 11/05/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971235
Principal investigator 1 ModernaTX, Inc. $33,601.50 11/05/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 11/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 11/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 11/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 11/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 11/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 11/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 11/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 11/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 11/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 11/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134609
Principal investigator 1 Janssen Research & Development, LLC $9,110.00 11/03/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175392137
Principal investigator 1 ModernaTX, Inc. $1,000.00 11/03/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $355.01 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $298.29 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $163.23 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $272.87 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.56 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $298.29 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62.88 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $298.29 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $163.23 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.56 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $165.58 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $163.23 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $339.03 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $355.01 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.56 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $368.63 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $298.29 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $207.77 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $298.29 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $163.23 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $322.13 10/31/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134589
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $169,225.00 10/28/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818330
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,008.00 10/28/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818332
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,844.00 10/28/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818334
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,825.00 10/28/2025 Covered Recipient Teaching Hospital
Orlando Health
131462 No dispute reported 06/30/2026 1252498739
Principal investigator 1 Iovance Biotherapeutics, Inc. $575.00 10/28/2025 Covered Recipient Teaching Hospital
Orlando Health
131462 No dispute reported 06/30/2026 1252498747
Principal investigator 1 Iovance Biotherapeutics, Inc. $32.80 10/28/2025 Covered Recipient Teaching Hospital
Orlando Health
81990 No dispute reported 06/30/2026 1252498757
Principal investigator 1 Janssen Research & Development, LLC $5,400.00 10/27/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175392420
Principal investigator 1 ModernaTX, Inc. $936.13 10/24/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971159
Principal investigator 1 ModernaTX, Inc. $41,763.51 10/22/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946686
Principal investigator 1 Janssen Research & Development, LLC $3,100.00 10/21/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1175392208
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,000.00 10/16/2025 Covered Recipient Teaching Hospital
Orlando Health
81990 No dispute reported 06/30/2026 1252498751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 10/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 10/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134513
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,934.60 10/15/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818328
Principal investigator 1 Janssen Research & Development, LLC $625.00 10/10/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175392403
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,450.00 10/07/2025 Covered Recipient Teaching Hospital
Orlando Health
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220818350
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,400.00 10/07/2025 Covered Recipient Teaching Hospital
Orlando Health
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220818352
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 10/06/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818326
Principal investigator 1 ModernaTX, Inc. $150.00 10/03/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946676
Principal investigator 1 ModernaTX, Inc. $12,576.00 10/03/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 10/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 10/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,550.00 10/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 10/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 10/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $925.00 10/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,175.00 10/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $925.00 10/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 10/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134505
Principal investigator 1 Immunocore Limited $1,000.00 10/02/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146053
Principal investigator 1 Immunocore Limited $1,000.00 10/02/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146055
Principal investigator 1 Immunocore Limited $1,000.00 10/02/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146057
Principal investigator 1 Immunocore Limited $13,743.35 09/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146043
Principal investigator 1 Immunocore Limited $1,049.31 09/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146045
Principal investigator 1 Immunocore Limited $3,170.20 09/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146047
Principal investigator 1 Immunocore Limited $1,000.00 09/24/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146049
Principal investigator 1 ModernaTX, Inc. $4,873.20 09/24/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 09/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 09/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 09/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 09/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99.56 09/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 09/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 09/24/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134469
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,290.33 09/16/2025 Covered Recipient Teaching Hospital
Orlando Health
81990 No dispute reported 06/30/2026 1252498133
Principal investigator 1 Immunocore Limited $575.00 09/12/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146029
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/12/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946718
Principal investigator 1 Immunocore Limited $1,046.24 09/10/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146027
Principal investigator 1 ModernaTX, Inc. $14,541.00 09/10/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946704
Principal investigator 1 ModernaTX, Inc. $12,576.00 09/10/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 09/10/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 09/10/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134439
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,869.20 09/08/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818322
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 09/03/2025 Covered Recipient Teaching Hospital
Orlando Health
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220818348
Principal investigator 1 Iovance Biotherapeutics, Inc. $625.00 09/02/2025 Covered Recipient Teaching Hospital
Orlando Health
131462 No dispute reported 06/30/2026 1252498147
Principal investigator 1 Iovance Biotherapeutics, Inc. $24,996.25 09/02/2025 Covered Recipient Teaching Hospital
Orlando Health
131462 No dispute reported 06/30/2026 1252498149
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,500.00 09/02/2025 Covered Recipient Teaching Hospital
Orlando Health
131462 No dispute reported 06/30/2026 1252498151
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,750.00 09/02/2025 Covered Recipient Teaching Hospital
Orlando Health
81990 No dispute reported 06/30/2026 1252498165
Principal investigator 1 Janssen Research & Development, LLC $7,236.00 09/01/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392182
Principal investigator 1 Janssen Research & Development, LLC $704.00 09/01/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392303
Principal investigator 1 Merck Sharp & Dohme LLC $33,210.40 08/31/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma INTerpath-001 No dispute reported 06/30/2026 1232937432
Principal investigator 1 Janssen Research & Development, LLC $460.00 08/28/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1175392244
Principal investigator 1 ModernaTX, Inc. $500.00 08/27/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946724
Principal investigator 1 ModernaTX, Inc. $1,000.00 08/27/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946726
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $925.00 08/20/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818318
Principal investigator 1 ModernaTX, Inc. $12,576.00 08/15/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946680
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,500.00 08/14/2025 Covered Recipient Teaching Hospital
Orlando Health
131462 No dispute reported 06/30/2026 1252498161
Principal investigator 1 Immunocore Limited $842.33 08/13/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146031
Principal investigator 1 ModernaTX, Inc. $10,742.00 08/13/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946688
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,000.00 08/06/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818320
Principal investigator 1 ModernaTX, Inc. $1,572.00 08/06/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971173
Principal investigator 1 ModernaTX, Inc. $3,276.44 08/06/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971191
Principal investigator 1 ModernaTX, Inc. $4,000.00 08/06/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971193
Principal investigator 1 ModernaTX, Inc. $14,934.00 08/06/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971207
Principal investigator 1 ModernaTX, Inc. $2,500.00 08/06/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971229
Principal investigator 1 ModernaTX, Inc. $2,000.00 08/06/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 08/06/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134403
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,934.60 08/04/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818324
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 08/04/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 08/04/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134401
Principal investigator 1 Immunocore Limited $1,000.00 08/01/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146023
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,032.26 08/01/2025 Covered Recipient Teaching Hospital
Orlando Health
81990 No dispute reported 06/30/2026 1252498175
Principal investigator 1 Janssen Research & Development, LLC $4,930.00 08/01/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392170
Principal investigator 1 Janssen Research & Development, LLC $19,480.00 07/29/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392153
Principal investigator 1 Janssen Research & Development, LLC $460.00 07/29/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392214
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $139.92 07/28/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220997718
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $479.52 07/28/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220997720
Principal investigator 1 ModernaTX, Inc. $1,572.00 07/25/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946692
Principal investigator 1 ModernaTX, Inc. $18,864.00 07/25/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946710
Principal investigator 1 ModernaTX, Inc. $11,461.09 07/25/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946712
Principal investigator 1 ModernaTX, Inc. $20,174.00 07/25/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946716
Principal investigator 1 ModernaTX, Inc. $1,965.00 07/25/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946736
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $393.00 07/24/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818316
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,383.62 07/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220810470
Principal investigator 1 Janssen Research & Development, LLC $25,201.00 07/22/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392160
Principal investigator 1 Immunocore Limited $1,500.00 07/21/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146033
Principal investigator 1 Immunocore Limited $1,450.00 07/21/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146035
Principal investigator 1 Immunocore Limited $2,000.00 07/21/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146037
Principal investigator 1 Immunocore Limited $500.00 07/21/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146039
Principal investigator 1 Immunocore Limited $1,000.00 07/21/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146041
Principal investigator 1 Janssen Research & Development, LLC $500.00 07/21/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392127
Principal investigator 1 Janssen Research & Development, LLC $28,826.00 07/21/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392297
Principal investigator 1 ModernaTX, Inc. $1,000.00 07/18/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946702
Principal investigator 1 ModernaTX, Inc. $1,000.00 07/18/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946714
Principal investigator 1 ModernaTX, Inc. $1,000.00 07/18/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $625.00 07/18/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 07/18/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $625.00 07/18/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 07/18/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134395
Principal investigator 1 ModernaTX, Inc. $500.00 07/16/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946708
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $375.00 07/11/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818314
Principal investigator 1 ModernaTX, Inc. $458.50 07/11/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971183
Principal investigator 1 ModernaTX, Inc. $3,930.00 07/11/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971197
Principal investigator 1 ModernaTX, Inc. $37,335.00 07/11/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971239
Principal investigator 1 Immunocore Limited $925.00 07/09/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146025
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 07/08/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818312
Principal investigator 1 Janssen Research & Development, LLC $700.00 07/08/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392315
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,645.60 07/07/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818310
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99.56 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99.56 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99.56 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99.56 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99.56 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $458.50 07/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/04/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/04/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/04/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/04/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/04/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/04/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,280.71 07/02/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134325
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,097.86 07/01/2025 Covered Recipient Teaching Hospital
Orlando Health
81990 No dispute reported 06/30/2026 1252498123
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,424.00 07/01/2025 Covered Recipient Teaching Hospital
Orlando Health
81990 No dispute reported 06/30/2026 1252498125
Principal investigator 1 Janssen Research & Development, LLC $9,191.00 07/01/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392107
Principal investigator 1 ModernaTX, Inc. $29,935.18 07/01/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946728
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,264.00 06/27/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818308
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,008.00 06/25/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818306
Principal investigator 1 Janssen Research & Development, LLC $8,377.00 06/23/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 06/23/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134281
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,300.00 06/20/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818304
Principal investigator 1 ModernaTX, Inc. $7,377.92 06/20/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971189
Principal investigator 1 Janssen Research & Development, LLC $1,116.00 06/17/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392120
Principal investigator 1 Janssen Research & Development, LLC $2,598.00 06/17/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392148
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 06/17/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223268726
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $625.00 06/16/2025 Covered Recipient Teaching Hospital
Orlando Health
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220818346
Principal investigator 1 Janssen Research & Development, LLC $4,700.00 06/16/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.70 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $561.99 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,406.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,323.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,585.00 06/16/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184134233
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,794.00 06/13/2025 Non-covered Recipient Entity
TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) No dispute reported 06/30/2026 1185538132
Principal investigator 1 ModernaTX, Inc. $15,700.16 06/12/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971227
Principal investigator 1 ModernaTX, Inc. $7,443.42 06/11/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971225
Principal investigator 1 ModernaTX, Inc. $500.00 06/11/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971233
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $752.56 06/04/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220810468
Principal investigator 1 ModernaTX, Inc. $1,500.00 06/04/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971163
Principal investigator 1 ModernaTX, Inc. $6,795.00 06/04/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971165
Principal investigator 1 ModernaTX, Inc. $500.00 06/04/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971195
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/04/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971213
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,250.00 05/27/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818302
Principal investigator 1 ModernaTX, Inc. $7,377.92 05/23/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971201
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $575.00 05/22/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818300
Principal investigator 1 ModernaTX, Inc. $3,000.00 05/21/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946696
Principal investigator 1 ModernaTX, Inc. $107.42 05/21/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971221
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $730.21 05/20/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220810466
Principal investigator 1 Janssen Research & Development, LLC $9,400.00 05/20/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392143
Principal investigator 1 Janssen Research & Development, LLC $1,260.00 05/19/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1175392114
Principal investigator 1 Janssen Research & Development, LLC $3,150.00 05/19/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1175392310
Principal investigator 1 Janssen Research & Development, LLC $3,301.20 05/19/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1175392366
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $665.00 05/19/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223268724
Principal investigator 1 Immunocore Limited $842.33 05/16/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146021
Principal investigator 1 ModernaTX, Inc. $4,873.20 05/16/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971223
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,250.00 05/15/2025 Covered Recipient Teaching Hospital
Orlando Health
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220818344
Principal investigator 1 ModernaTX, Inc. $1,500.00 05/14/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971171
Principal investigator 1 ModernaTX, Inc. $230.00 05/14/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,237.48 05/12/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134113
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,008.00 05/09/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818298
Principal investigator 1 Janssen Research & Development, LLC $7,454.00 05/08/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392274
Principal investigator 1 Janssen Research & Development, LLC $1,620.00 05/08/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1175392292
Principal investigator 1 ModernaTX, Inc. $312.04 05/07/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971167
Principal investigator 1 ModernaTX, Inc. $500.00 05/07/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971215
Principal investigator 1 ModernaTX, Inc. $1,241.49 05/07/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971219
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 05/05/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818296
Principal investigator 1 ModernaTX, Inc. $2,000.00 05/01/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946684
Principal investigator 1 ModernaTX, Inc. $1,500.00 05/01/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946690
Principal investigator 1 ModernaTX, Inc. $1,450.00 05/01/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946700
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $73.36 04/30/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $282.96 04/30/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $73.36 04/30/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184134095
Principal investigator 1 ModernaTX, Inc. $3,646.66 04/28/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971237
Principal investigator 1 Janssen Research & Development, LLC $170.00 04/25/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta No dispute reported 06/30/2026 1175392132
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $867.30 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997726
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $244.65 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997728
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $29.30 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997730
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2.20 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997732
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $174.90 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997734
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $39.96 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997736
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $255.50 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997738
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $488.56 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997740
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,305.00 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997742
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1.50 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997744
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $9.00 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997746
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.80 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997748
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $15.00 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997750
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $56.40 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997752
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $52.50 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997754
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $31.50 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997756
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $50.60 04/23/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220997758
Principal investigator 1 Janssen Research & Development, LLC $9,200.00 04/22/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392397
Principal investigator 1 ModernaTX, Inc. $17,824.16 04/16/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946678
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,575.00 04/15/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223268722
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,156.90 04/10/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818294
Principal investigator 1 ModernaTX, Inc. $3,000.00 04/07/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971199
Principal investigator 1 Immunocore Limited $1,000.00 04/04/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146019
Principal investigator 1 ModernaTX, Inc. $1,000.00 04/04/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971187
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 04/03/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818292
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,083.00 03/24/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818290
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,000.00 03/20/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223268718
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $23,503.75 03/13/2025 Covered Recipient Teaching Hospital
Orlando Health
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220818342
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,925.00 03/10/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818288
Principal investigator 1 Janssen Research & Development, LLC $4,839.60 03/10/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392338
Principal investigator 1 Immunocore Limited $633.72 03/07/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 03/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 03/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 03/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 03/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 03/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 03/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 03/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184133973
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,450.00 03/07/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223268716
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 03/06/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818284
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,469.90 03/06/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818286
Principal investigator 1 ModernaTX, Inc. $4,873.20 03/05/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,299.05 03/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $379.90 03/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,784.12 03/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $379.90 03/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,784.12 03/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,299.05 03/05/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133959
Principal investigator 1 Immunocore Limited $842.33 03/03/2025 Non-covered Recipient Entity
Orlando Health Inc.
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146015
Principal investigator 1 ModernaTX, Inc. $17,971.44 03/03/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971175
Principal investigator 1 Boehringer Ingelheim International GmbH $451.88 03/01/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
MRD Monotherapy, combination of VSV-GP w/ antiPD1 No dispute reported 06/30/2026 1220737636
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 02/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 02/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 02/28/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,299.05 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,784.12 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $379.90 02/27/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133901
Principal investigator 1 ModernaTX, Inc. $16,981.46 02/21/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946674
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,500.00 02/20/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $786.00 02/20/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,299.05 02/20/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133885
Principal investigator 1 ModernaTX, Inc. $14,934.00 02/19/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971179
Principal investigator 1 ModernaTX, Inc. $1,572.00 02/19/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971211
Principal investigator 1 ModernaTX, Inc. $625.00 02/19/2025 Covered Recipient Teaching Hospital
Orlando Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1252971241
Principal investigator 1 Janssen Research & Development, LLC $1,230.00 02/17/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1175392076
Principal investigator 1 Janssen Research & Development, LLC $495.00 02/17/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer No dispute reported 06/30/2026 1175392326
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,933.00 02/07/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818264
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,479.27 02/06/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818276
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,785.00 02/06/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818278
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 02/06/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818280
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $32,811.00 02/06/2025 Covered Recipient Teaching Hospital
Orlando Health
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma No dispute reported 06/30/2026 1236000404
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,000.00 02/05/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818274
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,195.93 02/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $572.47 02/03/2025 Covered Recipient Teaching Hospital
ORLANDO HEALTH
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer No dispute reported 06/30/2026 1184133867
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $900.00 02/01/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818272
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,879.80 01/30/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818270
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $100.00 01/29/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818268
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $399.60 01/27/2025 Non-covered Recipient Entity
Orlando Health Cancer Institute-Downtown Orlando
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220997716
Principal investigator 1 Janssen Research & Development, LLC $4,270.00 01/27/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392071
Principal investigator 1 Janssen Research & Development, LLC $24,913.00 01/23/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392268
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 01/23/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175392280
Principal investigator 1 ModernaTX, Inc. $11,602.54 01/17/2025 Covered Recipient Teaching Hospital
Orlando Health
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252971161
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 01/16/2025 Covered Recipient Teaching Hospital
Orlando Health
DAREON-8: A Phase I, open-label, dose escalation and expansion trial of repeated intravenous infusions of BI 764532 combined with Standard of care (platinium, etoposide, and anti-PD-L1) in patients with extensive-stage small cell lung carcinoma No dispute reported 06/30/2026 1220818266
Principal investigator 1 ModernaTX, Inc. $2,500.00 01/15/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946682
Principal investigator 1 ModernaTX, Inc. $18,000.00 01/15/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946734
Principal investigator 1 Janssen Research & Development, LLC $2,750.00 01/10/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta No dispute reported 06/30/2026 1175392331
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 01/10/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta No dispute reported 06/30/2026 1175392431
Principal investigator 1 ModernaTX, Inc. $625.00 01/03/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants with Solid Tumors No dispute reported 06/30/2026 1252946706